A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and Nab-paclitaxel (CP) with or without vorinostat as preoperative chemotherapy in HER2 negative primary operable breast cancer.

Trial Profile

A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and Nab-paclitaxel (CP) with or without vorinostat as preoperative chemotherapy in HER2 negative primary operable breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2015 Results of pooled analysis from this and other four trials presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2015 Interim results (n=48) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 18 Mar 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top